However, in agreement with our results showing a strong RAC3 cytoplasmic localization in CRC cells, additional not-nuclear effects could not be excluded, being perhaps an original and interesting point to be considered in order to design future improved therapies for CRC treatment. This evidence concerns the gene RAC3 and colorectal carcinoma.